Yoğun bakım ünitelerinde kan dolaşımı enfeksiyonu etkeni karbapenem dirençli Acinetobacter baumannii izolatlarının moleküler yöntemlerle karakterizasyonu
Amaç: Bu çalışmada; yoğun bakım ünitelerinde takip edilen hastaların kan örneklerinden izole edilen karbapenem dirençli Acinetobacter baumannii izolatları arasındaki klonal ilişki ve karbapenem direnç genlerinin moleküler yöntemler ile araştırılması amaçlandı. Yöntem: Kan kültürü şişelerinden bakteri izolasyonu için Bactec 9240 sistemi Becton Dickinson, ABD kullanıldı. Çalışmaya; konvansiyonel testler, API 20NE bioMèrieux, Fransa ve Phoenix TM 100 sistemi Becton Dickinson, ABD ile tanımlanan ve blaOXA-51 gen varlığı gösterilerek doğrulanan 112 A. baumannii suşu dahil edildi. Antimikrobiyal duyarlılık testleri Kirby-Bauer disk difüzyon yöntemi ve Phoenix TM 100 sistemi ile gerçekleştirildi. Karbapenem direnç genleri; blaOXA-23, blaOXA-48, blaOXA-58, blaIMP, blaVIM ve blaNDM-1 Multipleks Polimeraz Zincir Reaksiyonu PZR yöntemi ile araştırıldı. Acinetobacter baumannii suşları arasındaki klonal ilişkinin belirlenmesi için Pulse Field Jel Elektroforezi PFGE yöntemi kullanıldı. Bulgular: Suşların antibiyotik direnç yüzdeleri gentamisin, amikasin, tobramisin, netilmisin, seftazidim, trimetoprim/sulfametoksazol, piperasilin, siprofloksasin, ampisilin/sulbaktam, piperasilin/ tazobaktam ve sefoperazon/sulbaktam için sırasıyla %88; %81; %78; %36; %98,5; %96; %89; %100; %100; %93; %91 olarak bulundu. İmipenem ve meropenem MİK değerleri tüm grupta ≥8 µg/mL’nin üzerinde saptandı. Çalışmaya alınan izolatların tümünde blaOXA-51 ve blaOXA-23 gen varlığı tespit edildi. PFGE yöntemi ile 62 farklı pulsotip saptandı. Pulsotiplerden 19 tanesi birbiriyle ayırt edilemez profil gösteren eşittir üzeri ≥2 suş içermekteydi. Toplam 108 %96,4 suşun benzerlik oranı pulsotipler için %85 ve üzeri kabul edildiği durumda klonal yönden ilişkili 11 grup içerisinde toplandıkları gözlendi. Sonuç: Bu çalışmada, karbapenem dirençli A. baumannii suşlarının netilmisin dışında çalışılan tüm antibiyotiklere çok yüksek yüzdelerle dirence sahip olduğu ve hastane içinde çapraz bulaş yoluyla yayıldığı gösterildi. Bu suşlar hastane enfeksiyonları açısından risk oluşturmaktadır, bunula birlikte klonal yönden ilişkili suşlar spesifik bir ünite ve zaman periyodu ile sınırlı değildir.
Molecular characterisation of Carbapenem-resistant Acinetobacter baumannii bloodstream infections in intensive care units
Objective: In this study, the aim was to investigate the clonal relationship between carbapenem resistant Acinetobacter baumannii isolates and carbapenem resistance genes isolated from blood samples of patients followed in intensive care units by molecular methods. Methods: Bactec 9240 system Becton Dickinson, USA was used for the isolation of bacteria from blood culture flasks. Identification of 112 strains included in the study were performed by conventional tests, API 20NE bioMèrieux, France and Phoenix TM 100 system Becton Dickinson, USA and confirmed by the presence of blaOXA-51 gene. Antimicrobial susceptibility tests were performed by Kirby-Bauer disk diffusion method and Phoenix TM 100 system. Carbapenem resistance genes; blaOXA-23, blaOXA-48, blaOXA-58, blaIMP, blaVIM and blaNDM-1 were investigated by Multiplex Polymerase Chain Reaction PCR method. Pulsed Field Gel Electrophoresis PFGE was used to determine the clonal relationship between Acinetobacter baumannii strains. Results: The antibiotic resistance percentages of strains for gentamicin, amikacin, tobramycin, netil micin,ceftazidime,trimethoprim/sulfamethoxazole,piperacillin, ciprofloxacin, ampicillin/sulbactam, piperacillin/tazobactam and cefoperazone/ sulbactam, were 88%; 81%; 78%; 36%; 98.5%; 96%; 89%; 100%; 100%; 93%; 91% respectively. MIC values of imipenem and meropenem were determined above ≥8 µg/ml in the whole group. blaOXA-51 and blaOXA-23 genes were detected in all isolates included in the study. By PFGE method, 62 different pulsotypes were detected. Among the pulsotypes, 19 of them contained ≥2 strains. It was observed that 108 96.4% strains were clustered in 11 clonally related groups when the similarity between pulsotypes for grouping was limited to 85% or more. Conclusion: In this study, it was observed that carbapenem-resistant A. baumannii strains were resistant for all tested antibiotics at high levels except netilmicin and spread in the hospital via cross contamination. These strains posed a risk for hospital infections, however, clonal-related strains were not limited to a specific unit and time period.
___
- 1. Doi Y, Murray GL, Peleg AY. Acinetobacter
baumannii: evolution of Antimicrobial resistancetreatment options. Semin Respir Crit Care Med,
2015; 36(1): 85-98.
- 2. Lee HY, Chen CL, Wu SR, Huang C .W, Chiu CH.
Risk factors and outcome analysis of acinetobacter
baumannii complex bacteremia in critical patients.
Crit Care Med, 2014; 42(5): 1081-8.
- 3. Chusri S, Chongsuvivatwong V, Rivera JI,
Silpapojakul K, Singkhamanan K, McNeil E et al.
Clinical outcomes of hospital-acquired infection
with Acinetobacter nosocomialis and Acinetobacter
pittii. Antimicrob Agents Chemother, 2014; 58(7):
4172-9.
- 4. Wang J, Ruan Z, Feng Y, Fu Y, Jiang Y, Wang H et
al. Species distribution of clinical Acinetobacter
isolates revealed by different identification
techniques. PLoS One, 2014; 13;9(8),e104882.
- 5. Gerner-Smidt P, Tjernberg I, Ursing. Reliability of
phenotypic tests for identification of Acinetobacter
species. J Clin Microbiol, 1991; 29(2): 277-82.
- 6. Nemec A, Krizova L, Maixnerova M, Sedo O, Brisse
S, Higgins PG. Acinetobacter seifertii sp. nov.,
a member of the Acinetobacter calcoaceticusAcinetobacter baumannii complex isolated from
human clinical specimens. Int J Syst Evol Microbiol,
2015; 65(Pt 3): 934-42.
- 7. Cosgaya, C, Marí-Almirall M, Van Assche A,
Fernández-Orth D, Mosqueda N, Telli M et al.
Acinetobacter dijkshoorniae sp. nov., a member
of the Acinetobacter calcoaceticus-Acinetobacter
baumannii complex mainly recovered from clinical
samples in different countries. Int J Syst Evol
Microbiol, 2016; 66(10): 4105-11.
- 8. Wenzler E, Goff DA, Humphries R, Goldstein
EJC. Anticipating the Unpredictable: A review
of Antimicrobial Stewardship and Acinetobacter
Infections. Infect Dis Ther, 2017; 6(2): 149-72.
- 9. Lin MF, Lan CY. Antimicrobial resistance in
Acinetobacter baumannii: from bench to bedside.
World J Clin Cases, 2014; 2(12): 787-814.
- 10. Higgins PG, Dammhayn C, Hackel M, Seifert
H. Global spread of carbapenem-resistant
Acinetobacter baumannii. J Antimicrob Chemother,
2010; 65(2): 233-8.
- 11. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann
ME, Pitt TL. Identification of Acinetobacter
baumannii by detection of the blaOXA-51-like
carbapenemase gene intrinsic to this species. J Clin
Microbiol, 2006; 44(8): 2974-6.
- 12. Anonymous. Clinical and Laboratory Standards
Institute: Performance Standards for Antimicrobial
Susceptibility Testing. Twenty Fifth Informational
Supplement, M100-S25. ISBN: 1-56238-989-0,
Wayne, CLSI, 2015.
- 13. Gómez-Gil MR, Paño-Pardo JR, Romero-Gómez
MP, Gasior M, Lorenzo M, Quiles I, Mingorance J.
Detection of KPC-2-producing Citrobacter freundii
isolates in Spain. J Antimicrob Chemother, 2010;
65(12): 2695-7.
- 14. Garza-Ramos U, Morfin-Otero R, Sader HS, Jones
RN, Hernández E, Rodriguez-Noriega et al. Metallobeta-lactamase gene bla(IMP-15) in a class 1
integron, In95, from Pseudomonas aeruginosa
clinical isolates from a hospital in Mexico.
Antimicrob Agents Chemother, 2008; 52(8): 2943-6.
- 15. Poirel L, Bonnin RA, Nordmann P. Genetic
features of the widespread plasmid coding for
the carbapenemase OXA-48. Antimicrob Agents
Chemother, 2012; 56(1): 559-62.
- 16. Lim J, Cho HH, Kim S, Kim J, Kwon KC, Park JW,
Koo SH. The Genetic characteristics of Multidrugresistant Acinetobacter baumannii Coproducing 16S
rRNA Methylase armA and Carbapenemase OXA-23.
J Bacteriol Virol, 2013; (43)1: 27–36.
- 17. Anonymous. Center for disease control and
Prevention. Multiplex Real-Time PCR Detection of
Klebsiella pneumonia Carbapenemase (KPC) and
New Delhi metallo-β-lactamase (NDM-1) genes,
CDC . http://www.cdc. gov/HAI/settings/lab/kpcndm1-lab-protocol. (Erişim Tarihi: 2011).
- 18. Seifert H, Dolzani L, Bressan R, van der Reijden
T, van Strijen B, Stefanik D et al. Standardization
and interlaboratory reproducibility assessment
of pulsed-field gel electrophoresis-generated
fingerprints of Acinetobacter baumannii. J Clin
Microbiol, 2005; 43(9): 4328-35.
- 19. Tenover FC, Arbeit RD., Goering RV1. How to select
and interpret molecular strain typing methods for
epidemiological studies of bacterial infections: a
review for healthcare epidemiologists. Molecular
Typing Working Group of the Society for Healthcare
Epidemiology of America. Infect Control Hosp
Epidemiol, 1997; 18(6): 426–39.
- 20. Vincent JL, Rello J, Marshall J, Silva E, Anzueto
A, Martin CD et al. International study of the
prevalence and outcomes of infection in intensive
care units. JAMA, 2009; 2: 302(21): 2323-9.
- 21. Aydın M, Ergönül Ö, Azap A, Bilgin H, Aydın G, Çavuş
SA, et al. Rapid emergence of colistin resistance
and its impact on fatality among healthcareassociated infections. J Hosp Infect, 2018; 98(3):
260-3.
- 22. Zander E, Higgins PG, Fernández-González A,
Seifert H. Detection of intrinsic blaOXA-51-like
by multiplex PCR on its own is not reliable for the
identification of Acinetobacter baumannii. Int J
Med Microbiol, 2013; 303(2): 88-9.
- 23. Lee YT, Kuo SC, Chiang MC, Yang SP, Chen CP, Chen
TL, et al. Emergence of carbapenem-resistant
non-baumannii species of Acinetobacter harboring
a blaOXA-51-like gene that is intrinsic to A.
baumannii. Antimicrob Agents Chemother, 2012;
56(2): 1124-7.
- 24. Perez F, Hujer AM, Hujer KM, Decker BK, Rather
PN, Bonomo RA. Global challenge of multidrugresistant Acinetobacter baumannii. Antimicrob
Agents Chemother, 2007; 51(10): 3471-84.
- 25. Sarı AN, Biçmen M, Gülay Z. The first report on
the outbreak of OXA-24/40-like carbapenemaseproducing Acinetobacter baumannii in Turkey. Jpn
J Infect Dis, 2013; 66(5): 439-42.
- 26. Mugnier PD, Poirel L, Naas T, Nordmann P. Worldwide
dissemination of the blaOXA-23 carbapenemase
gene of Acinetobacter baumannii. Emerg Infect Dis,
2010; 16(1): 35-40.
- 27. Ozen N, Ergani A, Naas T, Ogunc D, Gultekin
M, Colak D, et al. Outbreak of CarbapenemResistant Acinetobacter baumannii producing
the carbapenemase OXA-58in Turkey. The Open
Antimicrob Agents J, 2009; 1: 1-8.
- 28. Vahaboglu H, Budak F, Kasap M, Gacar G, Torol S,
Karadenizli A, et al. High prevalence of OXA-51-
type class D beta-lactamases among ceftazidimeresistant clinical isolates of Acinetobacter spp.:
co-existence with OXA-58 in multiple centres. J
Antimicrob Chemother, 2006; 58(3): 537-42.
- 29. Kulah C, Mooij MJ, Comert F, Aktas E, Celebi G,
Ozlu N, et al. Characterisation of carbapenemresistant Acinetobacter baumannii outbreak strains
producing OXA-58 in Turkey. Int J Antimicrob
Agents, 2010; 36(2): 114-8.
- 30. Gur D, Korten V, Unal S, Deshpande LM, Castanheira
M. Increasing carbapenem resistance due to the
clonal dissemination of oxacillinase (OXA-23 and
OXA-58)-producing Acinetobacter baumannii:
report from the Turkish SENTRY Program sites. J
Med Microbiol, 2008; 57(Pt 12): 1529-32.
- 31. Ergin A, Hascelik G, Eser OK Molecular
characterization of oxacillinases and genotyping
of invasive Acinetobacter baumannii isolates using
repetitive extragenic palindromic sequence-based
polymerase chain reaction in Ankara between 2004
and 2010. Scand J Infect Dis, 2013; 45(1): 26-31.
- 32. Ahmed SS, Alp E, Ulu-Kilic A, Dinc G, Aktas Z, Ada B,
et al. Spread of carbapenem-resistant international
clones of Acinetobacter baumannii in Turkey
and Azerbaijan: a collaborative study. Eur J Clin
Microbiol Infect Dis, 2016; 35(9): 1463-8.
- 33. Ciftci IH, Aşık G, Karakeçe E, Oksüz L, Yağcı S,
Sesli Çetin E, et al. Distribution of blaOXA genes
in Acinetobacter baumannii strains: a multicenter
study]. Mikrobiyol Bul, 2013; 47(4): 592-602.
- 34. Keskin H, Tekeli A, Dolapci İ, Öcal D. Molecular
characterization of beta-lactamase-associated
resistance in Acinetobacter baumannii strains
isolated from clinical samples. Mikrobiyol Bul,
2014; 48(3): 365-76.
- 35. Castanheira M, Costello SE, Woosley LN,
Deshpande LM., Davies TA, Jones RN. Evaluation of
clonality and carbapenem resistance mechanisms
among Acinetobacter baumannii-Acinetobacter
calcoaceticus complex and Enterobacteriaceae
isolates collected in European and Mediterranean
countries and detection of two novel β-lactamases,
GES-22 and VIM-35. Antimicrob Agents Chemother,
2014; 58(12): 7358-66.
- 36. Anonymous. Surveillance of antimicrobial resistance
in Europe, Antimicrobial Resistance Surveillance
Network) 2016, Stockholm: ECDC; 2017. https://
ecdc.europa.eu/sites/portal/files/documents/
AMR-surveillance-Europe-2016.pdf (Erişim tarihi:
2017). doi 10.2900/296939.
- 37. Lob SH, Hoban DJ, Sahm DF, Badal E. Regional
differences and trends in antimicrobial
susceptibility of Acinetobacter baumannii. Int J
Antimicrob Agents, 2016; 47(4): 317-23.